Common Contracts
2 similar Equity Distribution Agreement contracts by NLS Pharmaceutics Ltd., Sigilon Therapeutics, Inc.
EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • April 14th, 2022 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations • New York
As further set forth in this agreement (this “Agreement”), Sigilon Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell from time to time through Canaccord Genuity LLC (the “Agent”), as sales agent, the Company’s common stock, $0.001 par value per share (the “Common Shares”) (such Common Shares to be sold pursuant to this Agreement, the “Shares”), having an aggregate offering price of up to $10,000,000, on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agent shall have no obligation in connection with such compliance.
NLS PHARMACEUTICS LTD. Common Shares (par value CHF 0.02 per share) ATM Sales AgreementEquity Distribution Agreement • March 4th, 2022 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations • New York
NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the “Company”), confirms its agreement (this “Agreement”) with Virtu Americas LLC (the “Agent”) as follows:
